RxDoctor Payments Data

Ian Dworkin

Pain Medicine · Los Angeles, CANPI 1861810368

Payments from drug & device makers

$18,944in general payments, 2019–2025

Across 411 payments — averaging $46.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Saluda Medical Americas, Inc.$3K
  • Boston Scientific$3K
  • Spinal Simplicity, LLC$1K
  • Nevro Corp.$878
  • Medtronic$745
  • plus $3K from 13 others

What the payments were for

  • Travel & lodging$5,66230%
  • Food & beverage$13,28370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,944 in reported general payments places this provider in the 85th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$83,660
Medicare patients
98
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl12$10,714
Baclofen223$2,128
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,707
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$1,287
Tizanidine Hcl37$951
Gabapentin83$928
Diclofenac Sodium24$545
Methadone Hcl18$308
Pregabalin23$307
Celecoxib16$255
Meloxicam90$251
Tramadol Hcl50$223
Acetaminophen-CodeineAcetaminophen With Codeine11$150
Methocarbamol11$137
Ibuprofen21$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$50$10,71412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 pain medicine providers in California.

Other pain medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →